JPMorgan Chase & Co. Has $62.85 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

JPMorgan Chase & Co. reduced its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 86.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 572,659 shares of the medical equipment provider’s stock after selling 3,767,609 shares during the quarter. JPMorgan Chase & Co.’s holdings in Lantheus were worth $62,849,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in Lantheus by 7.7% in the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after purchasing an additional 257,022 shares in the last quarter. Farallon Capital Management LLC grew its holdings in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock worth $182,999,000 after acquiring an additional 796,000 shares during the last quarter. Geode Capital Management LLC increased its position in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after acquiring an additional 19,071 shares during the last quarter. Finally, Swedbank AB lifted its position in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $91.21 on Friday. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The stock has a market cap of $6.34 billion, a P/E ratio of 15.18 and a beta of 0.45. The firm has a 50 day moving average price of $91.85 and a 200 day moving average price of $98.91.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research reports. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Truist Financial reissued a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $131.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.